INVAC-1

About Invectys

Invectys is a clinical-stage biotech developing cancer immunotherapies based on RNA and gene therapy platforms. The company's lead program, INVAC-1, is a telomerase-targeting therapeutic cancer vaccine that has progressed into Phase 2 clinical trials for various solid tumors. Founded on research from Institut Pasteur, Invectys leverages its expertise in antigen discovery and delivery to generate specific and durable anti-tumor immune responses. As a private company, it has secured funding from venture capital and strategic partnerships to advance its pipeline.

About Invectys

Invectys is a clinical-stage biotech developing cancer immunotherapies based on RNA and gene therapy platforms. The company's lead program, INVAC-1, is a telomerase-targeting therapeutic cancer vaccine that has progressed into Phase 2 clinical trials for various solid tumors. Founded on research from Institut Pasteur, Invectys leverages its expertise in antigen discovery and delivery to generate specific and durable anti-tumor immune responses. As a private company, it has secured funding from venture capital and strategic partnerships to advance its pipeline.

About Invectys

Invectys is a clinical-stage biotech developing cancer immunotherapies based on RNA and gene therapy platforms. The company's lead program, INVAC-1, is a telomerase-targeting therapeutic cancer vaccine that has progressed into Phase 2 clinical trials for various solid tumors. Founded on research from Institut Pasteur, Invectys leverages its expertise in antigen discovery and delivery to generate specific and durable anti-tumor immune responses. As a private company, it has secured funding from venture capital and strategic partnerships to advance its pipeline.

Therapeutic Areas

Other Head and Neck Squamous Cell Carcinoma Drugs